MK-2866 vs Retatrutide for weight loss
Short answer: For weight loss, users rate them about the same: 89% report improvement with MK-2866 (80 reports) and 91% with Retatrutide (222 reports).
MK-2866 has 0 meta-analyses and 0 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 612 reports about MK-2866 and 446 about Retatrutide. Not medical advice.
| MK-2866 SARM | Retatrutide Peptide | |
|---|---|---|
| User score | 33 | 71 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 39% | 76% |
| Reports | 612 | 446 |
| Research | DResearch: None | BResearch: Moderate |
| Meta-analyses / RCTs | 0 / 0 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 89% (80) | 91% (222) |
| Appetite % reporting improvement | 62% (8) | 73% (84) |
| Focus % reporting improvement | 71% (7) | 83% (6) |
| Energy % reporting improvement | 54% (37) | 69% (75) |
| Sleep % reporting improvement | 20% (20) | 31% (26) |
| Anxiety % reporting improvement | 33% (9) | 40% (5) |
| Mood % reporting improvement | 63% (49) | 66% (32) |
| Performance % reporting improvement | 88% (192) | 82% (33) |
| Recovery % reporting improvement | 97% (60) | 100% (8) |
| Pain & inflammation % reporting improvement | 70% (27) | 78% (9) |
| Digestion % reporting improvement | — | 46% (13) |
| Libido % reporting improvement | 31% (45) | 25% (12) |
| Hormones % reporting improvement | 4% (82) | 100% (13) |
| Blood sugar % reporting improvement | — | 75% (4) |
| Heart & lipids % reporting improvement | 0% (8) | 37% (19) |
| Skin & hair % reporting improvement | 33% (6) | — |
| Common side effects | suppression, fatigue, insomnia, headache | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | Not listed | Not listed |
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate